MVVC 2 - Field trials of a new combination malaria vaccine in West African Adults and Children
MVVC 2 - Field trials of a new combination malaria vaccine in West African Adults and Children
Objectives
The Malaria Vectored Vaccine Consortium (MVVC) 2 builds on the established network of MVVC 1, which aims to develop a malaria vaccine candidate, while building capacity at the African clinical trial sites and driving the development of a strong network of its partners.
This project will aim to determine whether addition of a circumsporozoite protein (CSP) particle in adjuvant will enhance the efficacy of vectored prime-boost vaccines for P. falciparum.
PI Institution(s)
Principal Investigator (PI)
Funding source(s)
Partner(s)
- University of Oxford
- National Center for Research and Training for Malaria (CNRFP), Burkina Faso
- Kenya Medical Research Institute (KEMRI)
- Cheikh Anta Diop University, Senegal
- Okairos, Italy
- Vienna School of Clinical Research (VSCR), Austria
- Medical Research Council (MRC) Unit, The Gambia
- Novartis Vaccines and Diagnostics, Italy
- Kintampo Health Research Centre (KHRC), Ghana